ArticleBMC infectious diseases2016
Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection.
Article in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04491799 (Fecal Calprotectin Level in Differentiating Between Inflammatory and Non-inflammatory Diarrhea in Patients With Nosocomial Diarrhea), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fecal Calprotectin Level in Differentiating Between Inflammatory and Non-inflammatory Diarrhea in Patients With Nosocomial Diarrhea
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- The value of fecal calprotectin inFrontiers in physiology · 2022Pooled it
- Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2020Pooled it
- Article
- Review
- "Antibiotics (Basel, Switzerland) · 2024Article
- Diagnostic Guidance for C. difficile Infections.Advances in experimental medicine and biology · 2024Article
- Fecal calprotectin level is nonlinearly associated with GI pathogen detection in patients with and without inflammatory bowel disease.Journal of clinical microbiology · 2023Article
- Stool Interleukin-1β Differentiates Clostridioides difficile Infection (CDI) From Asymptomatic Carriage and Non-CDI Diarrhea.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Microbiome profile and calprotectin levels as markers of risk of recurrentFrontiers in cellular and infection microbiology · 2023Article
- Epidemiologic Changes in Over 10 Years of Community-Acquired Bacterial Enteritis in Children.Pediatric gastroenterology, hepatology & nutrition · 2022Article
- The microbial diversity following antibiotic treatment of Clostridioides difficile infection.BMC gastroenterology · 2021Article
- Usefulness of Fecal Calprotectin in the Management of Patients with ToxigenicJournal of clinical medicine · 2021Article
- The xenobiotic sensing pregnane X receptor regulates tissue damage and inflammation triggered by C difficile toxins.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Impact of early-life events on the susceptibility to Clostridium difficile colonisation and infection in the offspring of the pig.Gut microbes · 2019Article
- Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Article
- Current knowledge on the laboratory diagnosis ofWorld journal of gastroenterology · 2017Review
- Role of Single Procalcitonin Test on Admission as a Biomarker for Predicting the Severity ofFrontiers in microbiology · 2017Article
- Clostridoides difficile Infection Severity Assessment by Fecal Calprotectin: A Pilot Study.Current health sciences journalArticle
- Clinical utility of fecal calprotectin: potential applications beyond inflammatory bowel disease for the primary care physician.Annals of gastroenterologyReview
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClostridium difficile is the most common infectious etiology of nosocomial diarrhea. Fecal calprotectin (fc) is a sensitive marker of intestinal inflammation, found to be associated with enteric bacterial infections and inflammatory bowel disease.
methodsWe evaluated fc levels using a Chemiluminescent immunoassay method, in hospitalized patients with C. difficile infection (CDI) diagnosed by molecular stool examination and assessed correlation with virulent ribotype 027 strain infection, antibiotic susceptibility by gradient Etest strip performed on C. difficile colonies and clinical and laboratory measures of disease severity. Statistical analysis was performed for correlation of fc levels with clinical and laboratory parameters, disease severity and patient outcomes.
resultsOverall 29 patients with CDI were admitted at the Poria medical center in northern Israel, during June 2014-May 2015. Resistance to metronidazole was found in 3 (10.3 %) isolates and to vancomycin in 5 (17.2 %) isolates. Regarding patient outcomes, within 30 days of CDI diagnosis, recurrence of disease occurred in 10 (34.5 %) patients and 2 patients (6.9 %) died. Seven (24.1 %) isolates were C. difficile ribotype 027. Mean fc level was 331.4 μg/g (21-932). Higher fc levels were found in patients with C. difficile ribotype 027 (p < 0.0005). Fc levels were also correlated with elevated peripheral blood white cell count (p = 0.0007). A trend for higher fc levels was found in patients with a higher clostridium severity score index (p = 0.0633). No correlation was found between fecal calprotectin levels and age, sex, functional status, community versus hospital acquired CDI, antibiotic susceptibility, fever, and creatinine levels.
conclusionsOur study highlights the fact that fc has a potential role as a biomarker of disease severity and binary toxin producing ribotype associated disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.